SecSonar.com

Monte Rosa Therapeutics, Inc. (GLUE)

Monte Rosa Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Monte Rosa Therapeutics, Inc. (GLUE) is a Biotechnology company based in US with a market capitalization of $1.3B. Free cash flow was negative at -$27.5M. This page tracks GLUE's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 142 employees · IPO Jun 24, 2021

Valuation

Valuation & price

$18.15 · as of May 17, 2026 · -28.3% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

5.44

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$25.31$14.75$4.19Jul 25Dec 25Jul 26Jul 7, 25$4.97Jul 9, 25$5.29Jul 11, 25$5.16Jul 15, 25$5.23Jul 17, 25$5.90Jul 21, 25$5.83Jul 23, 25$5.96Jul 25, 25$5.67Jul 29, 25$5.26Jul 31, 25$4.95Aug 4, 25$4.88Aug 6, 25$4.36Aug 11, 25$4.19Aug 13, 25$4.44Aug 15, 25$4.58Aug 19, 25$4.40Aug 21, 25$4.50Aug 25, 25$4.59Aug 27, 25$4.67Aug 29, 25$4.80Sep 3, 25$5.00Sep 5, 25$4.94Sep 9, 25$4.83Sep 11, 25$4.89Sep 16, 25$6.47Sep 18, 25$6.93Sep 22, 25$6.53Sep 24, 25$6.62Sep 26, 25$7.49Sep 30, 25$7.41Oct 2, 25$7.63Oct 6, 25$7.66Oct 8, 25$7.71Oct 10, 25$10.04Oct 14, 25$10.61Oct 16, 25$10.31Oct 21, 25$9.59Oct 23, 25$10.38Oct 27, 25$12.32Oct 29, 25$12.50Oct 31, 25$12.85Nov 4, 25$12.00Nov 6, 25$13.01Nov 10, 25$14.06Nov 12, 25$14.16Nov 14, 25$14.36Nov 18, 25$13.78Nov 20, 25$13.52Nov 25, 25$16.02Nov 28, 25$16.17Dec 2, 25$15.41Dec 4, 25$17.26Dec 8, 25$17.85Dec 10, 25$17.23Dec 12, 25$16.31Dec 16, 25$18.66Dec 18, 25$15.83Dec 22, 25$16.19Dec 24, 25$17.64Dec 29, 25$16.12Jan 2, 26$15.31Jan 6, 26$16.01Jan 8, 26$25.31Jan 12, 26$23.72Jan 14, 26$24.06Jan 16, 26$23.71Jan 21, 26$24.23Jan 23, 26$22.84Jan 27, 26$23.10Jan 29, 26$21.36Feb 2, 26$20.88Feb 4, 26$19.53Feb 9, 26$19.59Feb 11, 26$18.96Feb 13, 26$17.92Feb 18, 26$18.28Feb 20, 26$18.98Feb 24, 26$19.21Feb 26, 26$18.50Mar 2, 26$18.50Mar 4, 26$18.61Mar 6, 26$17.80Mar 10, 26$17.28Mar 12, 26$16.04Mar 17, 26$16.03Mar 19, 26$16.06Mar 23, 26$15.03Mar 25, 26$15.71Mar 27, 26$15.38Mar 31, 26$16.45Apr 2, 26$17.09Apr 7, 26$17.12Apr 9, 26$18.05Apr 13, 26$17.55Apr 15, 26$18.23Apr 17, 26$19.78Apr 22, 26$20.98Apr 24, 26$19.79Apr 28, 26$19.01Apr 30, 26$19.15May 4, 26$19.57May 6, 26$20.39May 8, 26$19.39May 12, 26$19.11May 14, 26$18.68May 18, 26$18.01May 20, 26$18.65May 22, 26$18.81May 28, 26$19.39Jun 1, 26$19.67Jun 3, 26$17.59Jun 5, 26$16.37Jun 9, 26$16.61Jun 11, 26$17.10Jun 15, 26$18.12Jun 17, 26$18.41Jun 22, 26$18.67Jun 24, 26$20.85Jun 26, 26$22.29Jul 2, 26$24.21
$4.1952-week range$25.31
Loading valuation history…

Fundamentals

Key fundamentals

$1.3B

Market cap

—

Revenue growth (YoY)

93.2%

Gross margin

-$27.5M

Free cash flow (USD)

-$337.9M

Net debt

Net cash position

12.4%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2019 → 2025

FY 2019$0.00FY 2020$0.00FY 2021$0.00FY 2022$0.00FY 2023$0.00FY 2024$75.6MFY 2025$123.7M
$0$123.7M

Free cash flow by year

2019 → 2025

FY 2019$-7.6MFY 2020$-26.4MFY 2021$-69.1MFY 2022$-105.4MFY 2023$-62.8MFY 2024$38.0MFY 2025$-27.5M
-$7.6M-$27.5M

Gross margin by year

2024 → 2025

FY 202489.3%FY 202593.2%
89.3%93.2%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

16

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $132K · 10b5-1 PlanJanku Filip · Chief Medical Officer · $132.5KJul 1, 2026Filing
  • Insider sellInsider Sell $231KManning Anthony M. · Director · $231.1KJun 30, 2026Filing
  • Insider sellInsider Sell $138K · 10b5-1 PlanJanku Filip · Chief Medical Officer · $137.7KJun 30, 2026Filing
  • Insider sellInsider Sell $60K · 10b5-1 PlanTownson Sharon · Chief Scientific Officer · $60KJun 25, 2026Filing
  • Insider sellInsider Sell $44K · 10b5-1 PlanChampoux Jennifer · Chief Operating Officer · $43.5KJun 25, 2026Filing
  • Insider sellInsider Sell $882K · 10b5-1 PlanJanku Filip · Chief Medical Officer · $882.2KJun 25, 2026Filing
  • Insider sellInsider Sell $57K · 10b5-1 PlanTownson Sharon · Chief Scientific Officer · $57KJun 18, 2026Filing
  • Insider sellInsider Sell $41K · 10b5-1 PlanChampoux Jennifer · Chief Operating Officer · $41.3KJun 18, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 11, 2026Filing
  • Insider sellInsider Sell $106K · 10b5-1 PlanWarmuth Markus · Director, President & CEO · $106.3KJun 2, 2026Filing

Questions

Frequently asked questions

What is Monte Rosa Therapeutics, Inc.'s market cap?

Monte Rosa Therapeutics, Inc. (GLUE) has a market capitalization of $1.3B.

What is GLUE's P/E ratio?

A meaningful P/E ratio is not available for GLUE — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is GLUE's price-to-book (P/B) ratio?

GLUE trades at 5.44 times book value per share.

Are insiders buying GLUE stock?

SEC Form 4 filings show no open-market insider buys at Monte Rosa Therapeutics, Inc. in the last 90 days (16 sells).

Same arena

Related companies in Biotechnology

WVE

Wave Life Sciences Ltd.

$1.3B

NKTR

Nektar Therapeutics

$1.3B

PGEN

Precigen, Inc.

$1.3B

MRVI

Maravai LifeSciences Holdings, Inc.

$1.3B

MNKD

MannKind Corporation

$1.2B

SEPN

Septerna, Inc.

$1.4B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.